
Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)
Description
Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)
Market Insight:
Systemic Lupus Erythematosus (SLE) is a multi-systemic, incurable autoimmune disease that affects almost every organ and organ system in the human body. The immune system attacks the body's own tissues in this condition, causing significant inflammation and tissue damage in the organs implicated. Swollen joints, unexplained fever, chest discomfort, hair loss, mouth ulcers, enlarged lymph nodes, severe tiredness, and red rashes on the face are some of the most prevalent symptoms of SLE.
SLE is a highly undertreated condition with few viable therapy choices available worldwide. GSK's Benlysta (authorised by the US FDA in 2011 and China's NMPA in 2019), Astra Zeneca's Saphnelo (approved by the FDA in August 2021), and RemeGen's telitacicept (approved by China's NMPA in 2021) are the only biologic therapies approved in this indication globally. However, given enormous unmet medical need, the market would expand in the coming years. The global systemic lupus erythematosus market is expected to reach US$2.18 billion in 2023, progressing at a CAGR of 7.52% over the forecasted period.
Segment Covered:
- By Product Type: The market report has segmented the global systemic lupus erythematosus market into six segments in terms of product type: Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others. The biologics segment lead the market with largest share. Demand for drugs with better efficacy and safety profile have increased among people. Biologics are safer than many other products, and can be used to treat women during pregnancy. The market is expected to grow at the highest CAGR, due to technological advancements in biologics.
- By Route of Administration: The report splits the global market into three segments on the basis of route of administration: Oral, Intravenous and Subcutaneous. The oral segment dominated the market by occupying maximum share of the market. Oral route of administration is convenient, safe and cost effective. Therefore, on most of the times, people prefer to use oral route of administration in SLE treatment. Subcutaneous segment is projected to grow at the highest CAGR over the forecast period.
- By End User: According to report, the market has been segmented into three segments, based on end user: Hospitals, Drug Lab and Others. The hospital segment dominated the market with majority share. The hospital segment is expected to grow rapidly due to initiatives taken by several government around the world. Some hospitals are also providing free treatment to the SLE patients. Demand for drugs is increasing with increasing number od SLE patients and therefore drug lab segment would also grow in the coming years.
According to this report, the global systemic lupus erythematosus market is divided into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The countries covered in North America region include the US, Canada, and Mexico, while Europe includes UK, Germany, France, Spain, Italy and Rest of Europe.
North America dominated the market, by occupying largest share of the global market. Factors such as increasing prevalence of lupus and presence of prominent players have supported the growth of the systemic lupus erythematosus market in the region. On the other hand, the Asia Pacific network detection and response market is the emerging region in the global market, due to increasing adoption of cloud-based solutions by both large enterprises and SMEs in the region.
Top Impacting Factors:
Growth Drivers
- Increasing Healthcare Expenditure
- Increasing Female Population
- Favorable Government Initiatives
- Rising Prevalence of SLE Disease
- Stringent Regulatory Environment
- High Cost of Drug Development
- Rising Clinical Trials
- Adoption of Stem Cell Therapy
- Rising Awareness Among People
- Driver: Increasing Healthcare Expenditure
- Challenge: Stringent Regulatory Environment
- Trend: Rising Awareness Among People
The COVID-19 Analysis:
In the early phases of the pandemic, the world was put under lockdown to stop the virus from spreading, suspending the majority of commercial operations. The lockdown had a huge influence on industries that are considered the backbone of the world economy, such as manufacturing, aviation, tourism, and so on, causing the global economy to enter a recession. The healthcare businesses encountered a number of challenges during the early stages of the pandemic. The availability of doctors, health workers as well as the supply of medical devices, diagnostics, and treatments, were all affected. Regular identification and treatment of other diseases were missed in the first half of 2020, because entire healthcare sector was focused on preventing, detecting and treating COVID-19.
On the contrary, as the lockdowns were gradually released near the second half of 2020, there was an increase in the number of patients seeking treatment for autoimmune diseases. Healthcare sector restored to normal as rate of transmission was reduced. Treatment for autoimmune diseases began at a better pace. As a result, COVID-19 had a short-term detrimental impact on the systemic lupus erythematosus market.
Analysis of Key Players:
The global market for systemic lupus erythematosus is fragmented. Most of the approved therapies for SLE are small molecule immunosuppressive agents such as azathioprine (first approved by the FDA in 1968), mycophenolate mofetil (first approved by the FDA in 1995) and methotrexate (first approved by the FDA in 1953), all of which are now off-patent and being marketed by multiple pharmaceutical companies in generic forms.
Beyond these small molecule drugs, there are currently two biologic drugs approved for the treatment of SLE globally: GSK’s belimumab (approved by the FDA in 2011 and NMPA in 2019) and RemeGen’s Telitacicept (approved by the NMPA in 2021 and not approved yet in the US). Beyond these two approved products, there are two innovative biologics for the treatment of SLE in phase III development in the US (along with eighteen other molecules in Phase I/II) and no Phase III pipeline assets in China (but five assets in Phase I/II). The key players of the global systemic lupus erythematosus market are:
- Novartis AG
- Hoffmann-LA-Roche Ltd.
- Pfizer, Inc.
- AstraZeneca Plc
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Abbvie, Inc
- Biotest AG
- Sanofi
- Boston Pharmaceuticals
- UCB SA
- RemeGen Co., Ltd.
- Amgen Inc.
- Xencor, Inc.
Table of Contents
135 Pages
- 1. Executive Summary
- 2. Introduction
- 2.1 Systemic Lupus Erythematosus (SLE): An Overview
- 2.2 Systemic Lupus Erythematosus (SLE) Segmentation: An Overview
- Table 1: Systemic Lupus Erythematosus (SLE) Segmentation
- 3. Global Market Analysis
- 3.1 Global Systemic Lupus Erythematosus Market: An Analysis
- 3.1.1 Global Systemic Lupus Erythematosus Market by Value
- Table 2: Global Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Billion)
- Table 3: Global Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
- 3.1.2 Global Systemic Lupus Erythematosus Market by Number of Patients
- Table 4: Global Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Million)
- Table 5: Global Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Million)
- 3.1.3 Global Systemic Lupus Erythematosus Market by Product Type (Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others)
- Table 6: Global Systemic Lupus Erythematosus Market by Product Type; 2021 (Percentage, %)
- 3.1.4 Global Systemic Lupus Erythematosus Market by Route of Administration (Oral, Intravenous and Subcutaneous)
- Table 7: Global Systemic Lupus Erythematosus Market by Route of Administration; 2021 (Percentage, %)
- 3.1.5 Global Systemic Lupus Erythematosus Market by End User (Hospitals, Drug Lab and Others)
- Table 8: Global Systemic Lupus Erythematosus Market by End User; 2021 (Percentage, %)
- 3.1.6 Global Systemic Lupus Erythematosus Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
- Table 9: Global Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
- 3.2 Global Systemic Lupus Erythematosus Market: Product Analysis
- 3.2.1 Global Biologics Systemic Lupus Erythematosus Market by Value
- Table 10: Global Biologics Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 11: Global Biologics Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.2.2 Global NSAIDs Systemic Lupus Erythematosus Market by Value
- Table 12: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 13: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.2.3 Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value
- Table 14: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 15: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.2.4 Global Corticosteroids Systemic Lupus Erythematosus Market by Value
- Table 16: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 17: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.2.5 Global Immunosuppressant Systemic Lupus Erythematosus Market by Value
- Table 18: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 19: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.2.6 Global Others Systemic Lupus Erythematosus Market by Value
- Table 20: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 21: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.3 Global Systemic Lupus Erythematosus Market: Route of Administration Analysis
- 3.3.1 Global Oral Systemic Lupus Erythematosus Market by Value
- Table 22: Global Oral Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 23: Global Oral Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
- 3.3.2 Global Intravenous Systemic Lupus Erythematosus Market by Value
- Table 24: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 25: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.3.3 Global Subcutaneous Systemic Lupus Erythematosus Market by Value
- Table 26: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 27: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.4 Global Systemic Lupus Erythematosus Market: End User Analysis
- 3.4.1 Global Hospitals Systemic Lupus Erythematosus Market by Value
- Table 28: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 29: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.4.2 Global Drug Lab Systemic Lupus Erythematosus Market by Value
- Table 30: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 31: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 3.4.3 Global Others Systemic Lupus Erythematosus Market by Value
- Table 32: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 33: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4. Regional Market Analysis
- 4.1 North America Systemic Lupus Erythematosus Market: An Analysis
- 4.1.1 North America Systemic Lupus Erythematosus Market by Value
- Table 34: North America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 35: North America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.1.2 North America Systemic Lupus Erythematosus Market by Region (The US, Canada and Mexico)
- Table 36: North America Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
- 4.1.3 The US Systemic Lupus Erythematosus Market by Value
- Table 37: The US Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 38: The US Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.1.4 The US Systemic Lupus Erythematosus Market by Number of Patients
- Table 39: The US Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Thousand)
- Table 40: The US Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Thousand)
- 4.1.5 Canada Systemic Lupus Erythematosus Market by Value
- Table 41: Canada Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 42: Canada Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.1.6 Mexico Systemic Lupus Erythematosus Market by Value
- Table 43: Mexico Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 44: Mexico Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2 Europe Systemic Lupus Erythematosus Market: An Analysis
- 4.2.1 Europe Systemic Lupus Erythematosus Market by Value
- Table 45: Europe Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 46: Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.2 Europe Systemic Lupus Erythematosus Market by Region (UK, Germany, France, Spain, Italy and Rest of Europe)
- Table 47: Europe Systemic Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
- 4.2.3 UK Systemic Lupus Erythematosus Market by Value
- Table 48: UK Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 49: UK Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.4 Germany Systemic Lupus Erythematosus Market by Value
- Table 50: Germany Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 51: Germany Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.5 France Systemic Lupus Erythematosus Market by Value
- Table 52: France Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 53: France Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.6 Spain Systemic Lupus Erythematosus Market by Value
- Table 54: Spain Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 55: Spain Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.7 Italy Systemic Lupus Erythematosus Market by Value
- Table 56: Italy Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 57: Italy Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.2.8 Rest of Europe Systemic Lupus Erythematosus Market by Value
- Table 58: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
- Table 59: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.3 Asia pacific Systemic Lupus Erythematosus Market: An Analysis
- 4.3.1 Asia pacific Systemic Lupus Erythematosus Market by Value
- Table 60: Asia pacific Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 61: Asia pacific Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.4 Middle East & Africa Systemic Lupus Erythematosus Market: An Analysis
- 4.4.1 Middle East & Africa Systemic Lupus Erythematosus Market by Value
- Table 62: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 63: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 4.5 Latin America Systemic Lupus Erythematosus Market: An Analysis
- 4.5.1 Latin America Systemic Lupus Erythematosus Market by Value
- Table 64: Latin America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
- Table 65: Latin America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
- 5. Impact of COVID-19
- 5.1 Impact of COVID-19
- 5.1.1 Impact of COVID-19 on Healthcare
- 5.1.2 Impact of COVID-19 on Systemic Lupus Erythematosus Market
- 6. Market Dynamics
- 6.1 Growth Drivers
- 6.1.1 Increasing Healthcare Expenditure
- Table 66: The US Health Consumption Expenditure as a Percentage of GDP; 2015-2020 (Percentage, %)
- 6.1.2 Increasing Female Population
- Table 67: Global Female Population of Age Group 15-44; 2005-2020 (Billion)
- 6.1.3 Rapid Urbanization
- Table 68: Global Urban Population as a Share of Total Population; 2016-2021 (Percentage, %)
- 6.1.4 Favorable Government Initiatives
- 6.1.5 Rising Prevalence of SLE Disease
- 6.2 Challenges
- 6.2.1 Stringent Regulatory Environment
- 6.2.2 High Cost of Drug Development
- 6.3 Trends
- 6.3.1 Rising Clinical Trials
- 6.3.2 Adoption of Stem Cell Therapy
- 6.3.3 Rising Awareness Among People
- 7. Competitive Landscape
- 7.1 The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
- Table 69: The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
- 7.2 The US and China Systemic Lupus Erythematosus Market players by Pipeline Biologics for SLE Treatment
- Table 70: The US and China Systemic Lupus Erythematosus Market Players by Pipeline Biologics for SLE Treatment
- 8. Company Profiles
- 8.1 Hoffmann-LA- Roche Ltd.
- 8.1.1 Business Overview
- 8.1.2 Operating Segments
- Table 71: Hoffmann-La-Roche Ltd. Sales by Business Divisions; 2021 (Percentage, %)
- 8.1.3 Business Strategies
- 8.2 Pfizer, Inc.
- 8.2.1 Business Overview
- 8.2.2 Operating Segments
- Table 72: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
- 8.2.3 Business Strategies
- 8.3 AbbVie, Inc.
- 8.3.1 Business Overview
- 8.3.2 Operating Segments
- Table 73: Abbvie, Inc. Net Revenues by Products; 2021 (Percentage, %)
- 8.3.3 Business Strategies
- 8.4 Novartis AG
- 8.4.1 Business Overview
- 8.4.2 Operating Segments
- Table 74: Novartis AG Net Sales by Segment; 2021 (Percentage, %)
- 8.4.3 Business Strategies
- 8.5 AstraZeneca Plc
- 8.5.1 Business Overview
- 8.5.2 Operating Segments
- Table 75: AstraZeneca Plc Total Revenue by Product; 2021 (Percentage, %)
- 8.5.3 Business Strategies
- 8.6 GlaxoSmithKline plc
- 8.6.1 Business Overview
- 8.6.2 Operating Segments
- Table 76: GlaxoSmithKline plc Turnover by Segments; 2021 (Percentage, %)
- 8.6.3 Business Strategies
- 8.7 Merck & Co., Inc.
- 8.7.1 Business Overview
- 8.7.2 Operating Segments
- Table 77: Merck & Co., Inc. Total Sales by Segments; 2021 (Percentage, %)
- 8.7.3 Business Strategies
- 8.8 UCB SA
- 8.8.1 Business Overview
- 8.8.2 Operating Regions
- Table 78: UCB SA Net Sales by Region; 2021 (Percentage, %)
- 8.8.3 Business Strategies
- 8.9 RemeGen Co., Ltd.
- 8.9.1 Business Overview
- 8.9.2 Operating Regions
- Table 79: RemeGen Co., Ltd. Revenue by Region; 2021 (Percentage, %)
- 8.9.3 Business Strategies
- 8.10 Amgen Inc.
- 8.10.1 Business Overview
- 8.10.2 Operating Region
- Table 80: Amgen Inc. Revenue by Region; 2021 (Percentage, %)
- 8.10.3 Business Strategies
- 8.11 Biotest AG
- 8.11.1 Business Overview
- 8.11.2 Operating Segments
- Table 81: Biotest AG Sales by Segment; 2021 (Percentage, %)
- 8.11.3 Business Strategies
- 8.12 Xencor, Inc.
- 8.12.1 Business Overview
- 8.12.2 Revenue By Operations
- Table 82: Xencor, Inc. Revenue by Operations; 2021 (Percentage, %)
- 8.12.3 Business Strategies
- 8.13 Sanofi
- 8.13.1 Business Overview
- 8.13.2 Operating Segments
- Table 83: Sanofi Net Sales by segments; 2021 (Percentage, %)
- 8.13.3 Business Strategies
- 8.14 Boston Pharmaceuticals
- 8.14.1 Business Overview
- 8.14.2 Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.